About this trial
The ability to move with ease is labelled as mobility. Limitations in mobility are frequent, recovery of these skills is crucial for physical performance which gives children valuable social possibilities and has long-term advantages for their physical and mental health. The high-level mobility assessment tool (HiMAT) is a unidimensional performance to measure the degree of high-level mobility in traumatic brain injury patients. The revised HiMAT has been utilised recently in paediatric populations to assess clinical trial outcomes and measure high-level motor skills.
Urdu translation of revised HiMAT will be executed by using forward backwards translation method. Two bilingual translators fluent in both Urdu and English languages will facilitate the researcher in the translation of the tool. This final translated version will be then tested for validity and reliability on all participants of the study. The psychometric properties of the tool will be assessed including reliability, internal consistency, and item discrimination.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Children with age group 5-12 years
No condition affecting mobility of children
Able to understand and follow instruction.
Can speak & understand language
Disqualifiers
Children with visual impairments.
Children with conditions affecting their mobility.
Children with any history of surgery in the past one year.
Children with any cardiorespiratory comorbidities.
Trial population
The sample size is 80.
Trial design
Other
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Revised High Level Mobility Assessment Tool (HiMAT)
HiMAT is a single dimensional inspection of high-level movability for those suffering from TBI. The revised HiMAT comprises of 8 items that evaluate (1) walk forward, (2) walk backwards, (3) walk on toes and (4) walk over obstacle, (5) running, (6) skipping, (7) hopping, and (8) bounding. HiMAT has also been used to assess mobility in children with healthy conditions or suffering from any neurological disorder
Sponsors and contacts
Click on the lead sponsor to view all of their trials.